944774-98-5

Basic information

• Product Name: 2-benzyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one
• Synonyms: 2-benzyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one
• CAS NO: 944774-98-5
• Molecular Formula: C14H18N2O2
• Molecular Weight: 246.30492
• Mol File: 944774-98-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-benzyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one(944774-98-5)
• EPA Substance Registry System: 2-benzyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one(944774-98-5)

Safety Data

• Hazardous Substances Data: 944774-98-5(Hazardous Substances Data)

Upstream product

• 775-16-6 N-benzyl-3-pyrrolidinone 
• 125033-36-5 3-aminomethyl-1-benzyl-3-hydroxypyrrolidine 
• 97266-84-7 5-benzyl-1-oxa-5-azaspiro[2.4]heptane 

Downstream Products

• 637039-01-1 tert-butyl 6-oxa-2,9-diazaspiro[4.5]decane-9-carboxylate 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.